Rat CK-MB (Creatine Kinase MB Isoenzyme) ELISA Kit

Name: Rat CK-MB (Creatine Kinase MB Isoenzyme) ELISA Kit
SKU: DEIA-FN285
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, plasma, cell culture supernatants, tissue homogenate

Species Reactivity

Rat

Detection Method

Sandwich ELISA

Intended Use

For quantitative detection of Rat CK-MB (Creatine Kinase MB Isoenzyme) in serum, plasma, tissue homogenates and other biological fluids.

Contents of Kit

1. 96-well strip plate (Dismountable), 1 plate
2. Lyophilized Standard, 2 vials
3. Sample/Standard dilution buffer, 20 mL
4. Biotin-detection antibody (Concentrated), 120 uL
5. Antibody dilution buffer, 10 mL
6. HRP-Streptavidin Conjugate(SABC), 120 uL
7. SABC dilution buffer, 10 mL
8. TMB substrate, 10 mL
9. Stop solution, 10 mL
10. Wash buffer (25X), 30 mL
11. Plate Sealer, 5 pieces
12. Product Manual, 1 copy

Storage

Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Precision

Intra-Assay: CV<8%
Inter-Assay: CV<10%

Detection Range

31.2-2000 pg/mL

Sensitivity

18.75 pg/mL

Standard Curve

Citations

Have you cited DEIA-FN285 in a publication? Let us know and earn a reward for your research.

Cyclocreatine Phosphate: A Novel Bioenergetic/Anti-Inflammatory Drug That Resuscitates Poorly Functioning Hearts and Protects against Development of Heart Failure

Salwa A Elgebaly, Charles Van Buren, Robert Todd, Robert Poston, Reem K Arafa, Nashwa El-Khazragy, Donald Kreutzer, Mostafa A Rabie, Ahmed F Mohamed, Lamiaa A Ahmed, Nesrine S El Sayed

Pharmaceuticals (Basel)2023 MarPubMed ID: 36986552Read Article

Applications: ELISA
Reactive species: Rat
"Abstract: Irreversible myocardial injury causes the exhaustion of cellular adenosine triphosphate (ATP) contributing to heart failure (HF). Cyclocreatine phosphate (CCrP) was shown to preserve myocardial ATP during ischemia and maintain cardiac function in various animal models of ischemia/reperfusion. We tested whether CCrP administered prophylactically/therapeutically prevents HF secondary to ischemic injury in an isoproterenol (ISO) rat model. Thirty-nine rats were allocated into five groups: control/saline, control/CCrP, ISO/saline (85 and 170 mg/kg/day s.c. for 2 consecutive days), and ISO/CCrP (0.8 g/kg/day i.p.) either administrated 24 h or 1 h before ISO administration (prophylactic regimen) or 1 h after the last ISO injection (therapeutic regimen) and then daily for 2 weeks. CCrP protected against ISO-induced CK-MB elevation and ECG/ST changes when administered prophylactically or therapeutically. CCrP administered prophylactically decreased heart weight, hs-TnI, TNF-α, TGF-β, and caspase-3, as well as increased EF%, eNOS, and connexin-43, and maintained physical activity. Histology indicated a marked decrease in cardiac remodeling (fibrin and collagen deposition) in the ISO/CCrP rats. Similarly, therapeutically administered CCrP showed normal EF% and physical activity, as well as normal serum levels of hs-TnI and BNP. In conclusion, the bioenergetic/anti-inflammatory CCrP is a promising safe drug against myocardial ischemic sequelae, including HF, promoting its clinical application to salvage poorly functioning hearts."
Article snippet: Twenty-four hours after the last ISO injection, serum samples were collected to measure the levels of CK-MB using the rat creatine kinase MB isoenzyme ELISA Kit (Cat. No.DEIA-FN285; Creative Diagnostics, USA).

Prophylactic CCrP treatment prevented myocardial ischemic injury, and both ST-segment and CK-MB levels were normalized compared with ISO/saline rats. (Salwa A Elgebaly, <i>et al</i>, 2023)

Figure 1. CCrP prophylactically administered in rats before the first ISO injection prevents myocardial ischemic injury and cardiac dysfunction measured 24 h after the second ISO injection

Astaxanthin mitigates diabetic cardiomyopathy and nephropathyin HF/HFr/STZ diabetic rats via modulating NOX4, fractalkine, Nrf2, and AP-1 pathways

El-Nasr NMEA, Hussien YA, El-Baset MA, Shabana ME, Saleh DO

Sci Rep2025 Jun 20PubMed ID:40542047Read Article

Applications: ELISA
Reactive species: Rats
"Abstract: This study investigated the effects of astaxanthin (ASTA) on diabetic cardiomyopathy (DCM) and nephropathy (DN) in rats. Type 2 diabetes was induced through a high-fat/high-fructose (HF/HFr) diet followed by a sub-diabetogenic dose streptozotocin injection. Diabetic rats were treated with ASTA at a dose of 100 mg/kg for four weeks. Serum markers of renal and cardiac function, oxidative stress parameters, and electrocardiographic (ECG) measurements were assessed. Diabetic control rats exhibited significant impairment in renal and cardiac functions, heightened oxidative stress, and altered ECG parameters. Treatment with ASTA (100 mg/kg) markedly improved these conditions, proven by reduction in serum urea, creatinine, cardiac creatine phosphokinase-MB (CK-MB), and LDH levels. Additionally, oxidative stress markers such as MDA, GSH, SOD, and NOX4 were restored in both heart and kidney tissues. Furthermore, ASTA was able to increase the cardiac and renal Fractalkine chemokine as well as attenuate the elevated Nrf2 and AP-1. ECG abnormalities were partially reversed, with enhancements in the QTc interval and ST segment height. The histopathological examination of cardiac and renal tissues confirmed these results. Finally, the forementioned promising observations suggest that ASTA may offer therapeutic potential in mitigating DCM and DN via modulation of NOX4, Fractalkine, Nrf2, and AP-1 Pathway, warranting further research into its mechanisms and clinical applicability."
Article snippet: CK-MB and LDH levels were measured using ELISA kits (Creative Diagnostics, Catalog No. DEIA-FN285) and (***).

As depicted in figure 4 the DC group showed significant increases in serum CK-MB; serving as a marker for cardiac muscle damage, LDH, urea, and creatinine approximately by 2-, 2-, 5-and 3-fold, respectively suggested tissue damage and indicated kidney impairment beside reduced glomerular filtration rate as compared to the normal control group. (El-Nasr NMEA, <i>et al</i>, 2025)

Figure 1. Effect of ASTA on Serum Markers of Cardiac and Renal Function of HF/HFr/STZ induced Diabetic Complications in Rats.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Implementation of a Comprehensive ST-Elevation Myocardial Infarction Protocol Improves Mortality Among Patients With ST-Elevation Myocardial Infarction and Cardiogenic Shock

AMERICAN JOURNAL OF CARDIOLOGY

Authors: Kumar, Anirudh; Huded, Chetan P.; Zhou, Leon; Krittanawong, Chayakrit; Young, Laura D.; Krishnaswamy, Amar; Menon, Venu; Lincoff, A. Michael; Ellis, Stephen G.; Reed, Grant W.; Kapadia, Samir R.; Khot, Umesh N.

Abstract

Mortality in patients with STEMI-associated cardiogenic shock (CS) is increasing. Whether a comprehensive ST-elevation myocardial infarction (STEMI) protocol (CSP) can improve their care delivery and mortality is unknown. We evaluated the impact of a CSP on incidence and outcomes in patients with STEMI-associated CS. We implemented a 4-step CSP including: (1) Emergency Department catheterization lab activation; (2) STEMI Safe Handoff Checklist; (3) immediate catheterization lab transfer; (4) and radial-first percutaneous coronary intervention (PCI). We studied 1,272 consecutive STEMI patients who underwent PCI and assessed for CS incidence per National Cardiovascular Data Registry definitions within 24-hours of PCI, care delivery, and mortality before (January 1, 2011, to July 14, 2014; n = 723) and after (July 15, 2014, to December 31, 2016; n = 549) CSP implementation. Following CSP implementation, CS incidence was reduced (13.0% vs 7.8%, p = 0.003). Of 137 CS patients, 43 (31.4%) were in the CSP group. CSP patients had greater IABP-Shock II risk scores (1.9 +/- 1.8 vs 2.8 +/- 2.2, p = 0.014) with otherwise similar hemodynamic and baseline characteristics, cardiac arrest incidence, and mechanical circulatory support use. Administration of guideline-directed medical therapy was similar (89.4% vs 97.7%, p = 0.172) with significant improvements in trans-radial PCI (9.6% vs 44.2%, p < 0.001) and door-to-balloon time (129.0 [89:160] vs 95.0 [81:116] minutes, p = 0.001) in the CSP group, translating to improvements in infarct size (CK-MB 220.9 +/- 156.0 vs 151.5 +/- 98.5 ng/ml, p = 0.005), ejection fraction (40.8 +/- 14.5% vs 46.7 +/- 14.6%, p = 0.037), and in-hospital mortality (30.9% vs 14.0%, p = 0.037). In conclusion, CSP implementation was associated with improvements in CS incidence, infarct size, ejection fraction, and in-hospital mortality in patients with STEMI-associated CS. This strategy offers a potential solution to bridging the historically elusive gap in their care. (c) 2020 The Authors. Published by Elsevier Inc.

Cardioprotective effect of the polysaccharide from Ophiopogon japonicus on isoproterenol-induced myocardial ischemia in rats

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Authors: Fan, Sairong; Zhang, Junfeng; Xiao, Qi; Liu, Peng; Zhang, Yining; Yao, Enze; Chen, Xiaoming

Abstract

The polysaccharide (OJP1), extracted from the root of Ophiopogon japonicus, is a well-known traditional Chinese medicine used to treat cardiovascular diseases. The present study was set up to investigate the cardioprotective effect of OJP1 on isoproterenol (ISO)-induced myocardial ischemia injury in rats. Results showed that pretreatment with OJP1 (100, 200 and 300 mg/kg) significantly reduced ISO-induced ST-segment elevation and the heart index, attenuated the levels of marker enzymes (AST, LDH, CK and CK-MB), along with a significantly enhanced the activities of ATPases. Moreover, pretreatment with OJP1 not only enhanced the activities of SOD, GPx and CAT in serum and myocardium, but also decreased the level of MDA. The biochemical and histopathological analysis also showed that OJP1 can alleviate the myocardial injury induced by ISO. Taken together, our results indicated that oral administration of OJP1 offered significant cardioprotective effect against the damage induced by ISO through enhancement of endogenous antioxidants. (C) 2020 Elsevier B.V. All rights reserved.